title: Biocompatibility of an experimental MTA sealer implanted in the rat subcutaneous: quantitative and immunohistochemical evaluation.
abstract: The tissue reaction promoted by an experimental mineral trioxide aggregate sealer (MTAS) in the rat subcutaneous was evaluated by morphological and morphometric analyses. In the animals from each group (n = 20), polyethylene tubes filled with MTAS, Portland cement (PC) or MTA were implanted in the dorsal subcutaneous. In the control group, empty tubes were implanted. After 7, 14, 30, and 60 days, the specimens were fixed and embedded in paraffin. In the HE-stained sections, the numerical density of inflammatory cells (IC) in the capsule was evaluated and statistical analyses performed (p ≤ 0.05). The expression of osteopontin (OPN) was evaluated by immunohistochemistry. The von Kossa method for detection of calcified structures was also performed. A moderate inflammatory process in the capsule was seen in all groups, at 7 and 14 days. At 60 days, significant reduction in the number of IC was verified in comparison to initial periods; however, significant differences were not verified among the groups. OPN immunolabeling was observed in the fibroblasts cytoplasm of the capsule next to the implants. Structures von Kossa-positive were observed in the capsule adjacent to all materials implanted at 7, 14, and 30 days. The results strongly indicate that MTAS presents biocompatibility similarly to MTA and PC.
authors: Department of Restorative Dentistry, Dental School, UNESP-Universidade Estadual Paulista, Araraquara, São Paulo, Brazil.
authors: Naiana Viana
authors: NV
authors: Viola
authors: Juliane Maria
authors: JM
authors: Guerreiro-Tanomaru
authors: Guilherme Ferreira
authors: GF
authors: da Silva
authors: Estela
authors: E
authors: Sasso-Cerri
authors: Mario
authors: M
authors: Tanomaru-Filho
authors: Paulo Sérgio
authors: PS
authors: Cerri
mesh_terms: D017607:Aluminum Compounds / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D002113:Calcification, Physiologic / Q000187:drug effects*; D017610:Calcium Compounds / Q000009:adverse effects / Q000494:pharmacology*; D004338:Drug Combinations; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism*; D015743:Giant Cells, Foreign-Body / Q000166:cytology / Q000378:metabolism*; D007150:Immunohistochemistry; D008297:Male; D008422:Materials Testing; D010087:Oxides / Q000009:adverse effects / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012387:Root Canal Filling Materials / Q000009:adverse effects / Q000494:pharmacology*; D017640:Silicates / Q000009:adverse effects / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D017607:Aluminum Compounds; D017610:Calcium Compounds; D004338:Drug Combinations; D010087:Oxides; D012387:Root Canal Filling Materials; D017640:Silicates; C086631:mineral trioxide aggregate